Gemtuzumab ozogamicin is administered intravenously (IV) in a hospital or clinic setting by healthcare professionals experienced in the treatment of leukemia and the administration of cytotoxic agents. It is not an oral medication.
- Administration Route: Intravenous infusion.
- Preparation: It is provided as a lyophilized powder for reconstitution and further dilution before infusion. Strict aseptic technique must be followed.
- Infusion Duration: The diluted solution is typically infused slowly over 2 hours.
- Premedication: Patients are usually premedicated one hour prior to each infusion with a corticosteroid (e.g., methylprednisolone), an antihistamine (e.g., diphenhydramine), and acetaminophen to reduce the risk of infusion-related reactions.
- Dosage and Schedule: The dosage and schedule vary significantly based on the indication (newly diagnosed vs. relapsed/refractory) and whether it’s used as monotherapy or in combination with chemotherapy.
- Newly Diagnosed AML (Combination Regimen): Typically 3 mg/m² (up to a maximum of 4.5 mg/dose) on Days 1, 4, and 7 of the induction cycle, in combination with daunorubicin and cytarabine. For subsequent consolidation cycles, it’s often 3 mg/m² on Day 1. GO is typically not given in a second induction cycle.
- Newly Diagnosed AML (Single Agent – for patients not candidates for intensive chemotherapy): For adults, an induction dose might be 6 mg/m² on Day 1 and 3 mg/m² on Day 8, followed by continuation therapy.
- Relapsed or Refractory AML (Single Agent): Typically 3 mg/m² on Days 1, 4, and 7 for one course.
- Monitoring During Infusion: Patients are closely monitored for infusion-related reactions during the infusion and for at least 1 hour following completion.
- Dosage Modifications: Dosing modifications may be necessary based on adverse reactions, particularly liver toxicity (e.g., veno-occlusive disease) and hematologic parameters.
Gemtuzumab ozogamicin functions as a “guided missile” to specifically deliver a potent cytotoxic agent to AML cells. Its mechanism involves several steps:
- Targeted Binding: The gemtuzumab antibody component selectively binds to the CD33 antigen expressed on the surface of CD33-positive AML cells.
- Internalization: Once bound, the antibody-drug conjugate (GO-CD33 complex) is rapidly internalized by the cancer cell through a process called endocytosis.
- Release of Cytotoxic Agent: Inside the cell, typically within lysosomes (acidic cellular compartments), a specialized linker connecting the antibody and the cytotoxic agent is cleaved. This releases the active form of ozogamicin (calicheamicin derivative).
- DNA Damage and Cell Death: The released calicheamicin then travels to the cell nucleus, where it binds to DNA and causes single- and double-strand DNA breaks. This extensive DNA damage leads to cell cycle arrest and ultimately triggers apoptosis (programmed cell death) in the leukemic cells.
This targeted approach aims to minimize damage to healthy cells that do not express CD33, thereby reducing systemic toxicity compared to conventional chemotherapy, though significant side effects can still occur.
Gemtuzumab ozogamicin carries significant risks of serious and potentially fatal side effects, leading to a Black Box Warning in its prescribing information.
- Black Box Warning:
- Hepatotoxicity, including Veno-occlusive Liver Disease (VOD) / Sinusoidal Obstruction Syndrome (SOS): This is a serious and potentially fatal liver condition characterized by blocked blood vessels in the liver. The risk is significantly increased in patients who have undergone or are scheduled for hematopoietic stem cell transplantation (HSCT) before or after GO treatment. Symptoms include rapid weight gain, abdominal tenderness, ascites (fluid in the abdomen), and jaundice.
- Hemorrhage: Severe and sometimes fatal bleeding events (hemorrhage) have occurred.
- Other Serious Side Effects:
- Infusion-Related Reactions (IRRs): Can be severe, including anaphylaxis, chills, fever, dyspnea (shortness of breath), hypotension, and chest pain. These can occur during or shortly after infusion.
- Myelosuppression: Profound and prolonged suppression of bone marrow function leading to severe neutropenia (low white blood cells), thrombocytopenia (low platelets leading to bleeding/bruising), and anemia (low red blood cells). This is expected given its anti-leukemic action, but can be severe.
- Infections: Due to myelosuppression, patients are at increased risk of serious, life-threatening, or fatal infections (bacterial, viral, fungal).
- QT Interval Prolongation: Can cause a change in the heart’s electrical activity that can lead to a dangerous irregular heartbeat.
- Gastrointestinal Toxicities: Nausea, vomiting, diarrhea, mucositis (inflammation of mucous membranes), abdominal pain.
- Tumor Lysis Syndrome (TLS): Rapid breakdown of cancer cells can release harmful substances into the blood, leading to kidney failure, heart rhythm problems, and seizures.
- Embryo-Fetal Toxicity: Can cause harm to a fetus. Effective contraception is required for both male and female patients during and after treatment.
Given the severe potential side effects, strict monitoring and precautions are essential when using Gemtuzumab ozogamicin.
- Hepatotoxicity/VOD/SOS: This is a critical concern. Closely monitor liver function tests (bilirubin, AST, ALT) and signs/symptoms of VOD/SOS. Discontinue GO if VOD/SOS occurs. Exercise extreme caution in patients with prior liver disease or those undergoing HSCT.
- Infusion-Related Reactions: Patients must be premedicated and closely monitored during and after infusion. Management includes interrupting the infusion, administering supportive care, and restarting at a slower rate if symptoms resolve.
- Hemorrhage: Monitor for signs of bleeding. Manage with supportive care including transfusions.
- Myelosuppression: Frequent monitoring of complete blood counts is necessary. Dose adjustments or delays may be required.
- Infections: Prophylactic antibiotics may be used. Closely monitor for any signs of infection.
- QT Prolongation: Use with caution in patients with pre-existing cardiac conditions, electrolyte abnormalities, or concomitant use of QT-prolonging drugs. ECG monitoring may be required.
- Embryo-Fetal Toxicity: Advise pregnant women of the potential risk to the fetus. Females of reproductive potential must use effective contraception during treatment and for at least 6 months after the last dose. Males with female partners of reproductive potential must use effective contraception during treatment and for at least 3 months after the last dose.
- Contralateral AML: Use in patients with AML arising from myelodysplastic syndrome (MDS) has not been extensively studied.
- Leukostasis: In patients with high white blood cell counts (≥30,000 cells/mm3), cytoreduction (e.g., leukapheresis, hydroxyurea) is recommended prior to GO administration to reduce the risk of tumor lysis syndrome and other complications.
Due to its potent and specific nature, gemtuzumab ozogamicin can have interactions with other medications, particularly those affecting the bone marrow, liver, or heart, or those that are also used in cancer treatment.
- Myelosuppressive Agents: Concurrent use with other myelosuppressive (bone marrow suppressing) agents can increase the risk and severity of hematologic toxicities (e.g., severe neutropenia, thrombocytopenia). Careful monitoring of blood counts is crucial.
- Hepatotoxic Agents: Given GO’s risk of hepatotoxicity, caution is advised when administering it with other drugs known to cause liver damage.
- Anthracyclines (e.g., Daunorubicin): When used in combination chemotherapy for newly diagnosed AML, the specific timing and dosing are critical. Delaying the first dose of an anthracycline after GO administration, or modifying the GO schedule, may be considered to mitigate toxicity.
- Cardiac Medications (QT Prolongation): GO can cause QT interval prolongation. Concomitant use with other drugs known to prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics, antidepressants) or in patients with pre-existing cardiac conditions should be done with extreme caution, and ECG monitoring may be required.
- Live Vaccines: Avoid the administration of live vaccines concurrently with GO, as the patient’s immune system may be compromised.
- CYP Enzyme Substrates: While not a strong inhibitor, GO might have minor effects on certain CYP enzymes. Clinical significance is generally low, but caution is warranted with drugs that have a narrow therapeutic index and are substrates of these enzymes.
Always inform your healthcare provider about all medications, supplements, and herbal products you are taking.
Gemtuzumab ozogamicin dosage is precise and dependent on the patient’s condition, age, and whether it’s used alone or in combination. It is calculated based on body surface area (BSA) for most patients, or weight for very young children.
- Reconstitution and Dilution: Must be carefully reconstituted with sterile water for injection and then further diluted in 100 mL of 0.9% sodium chloride or 5% dextrose in water.
- Administration: Administered as an intravenous infusion over 2 hours.
- Adult Dosing:
- Newly Diagnosed CD33-positive AML (in combination with chemotherapy):
- Induction Cycle 1: 3 mg/m² (maximum 4.5 mg/dose) on Days 1, 4, and 7.
- Consolidation Cycles: 3 mg/m² (maximum 4.5 mg/dose) on Day 1.
- Newly Diagnosed CD33-positive AML (monotherapy, for patients not candidates for intensive chemotherapy):
- Induction: 6 mg/m² on Day 1 and 3 mg/m² on Day 8.
- Continuation: 2 mg/m² on Day 1 every 4 weeks for up to 8 cycles.
- Relapsed or Refractory CD33-positive AML (monotherapy): 3 mg/m² (maximum 4.5 mg/dose) on Days 1, 4, and 7 for a single course.
- Pediatric Dosing:
- Newly Diagnosed CD33-positive AML (1 month and older, in combination with chemotherapy):
- BSA ≥0.6 m2: 3 mg/m²
- BSA <0.6 m2: 0.1 mg/kg
- Given once in induction cycle 1.
- Relapsed or Refractory CD33-positive AML (2 years and older, monotherapy): 3 mg/m² (maximum 4.5 mg/dose) on Days 1, 4, and 7 for a single course.
- Premedication: Mandatory premedication as described above.
- Dosage Adjustments: Adjustments are made for liver toxicity, persistent hematologic toxicities, and other severe non-hematologic toxicities. Contraindicated in patients with severe hepatic impairment or end-stage renal disease (ESRD).
Gemtuzumab ozogamicin (Mylotarg) is a highly specialized prescription-only medication used in oncology. It requires expert administration and monitoring.
- Oncology Specialist: It must be prescribed and administered by physicians experienced in the diagnosis and treatment of acute myeloid leukemia, often in collaboration with hematology/oncology teams.
- Hospital/Specialized Clinic Setting: Administration requires an inpatient or specialized outpatient clinic setting with immediate access to equipment and personnel to manage infusion-related reactions and other acute toxicities.
- Close Monitoring: Patients receiving Gemtuzumab ozogamicin require intensive monitoring of blood counts, liver function, and overall clinical status throughout treatment and for an extended period afterward due to the risk of delayed toxicities like VOD/SOS.
- Risk Evaluation and Mitigation Strategy (REMS): In some regions (e.g., USA), it may be subject to a REMS program to ensure safe use, due to the serious risks of hepatotoxicity and veno-occlusive disease.
